Mebendazole potentiates radiation therapy in triple-negative breast cancer
In this study, a common antihelminthic drug, mebendazole (MBZ) is shown to deplete breast cancer stem cells in a TNBC model and act as a potent radiosensitizer in vitro and in vivo. These results strongly support the repurposing of MBZ as a radiosensitizer for the treatment of TNBC patients in combination with radiation therapy.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Le Zhang, Milana Bochkur Dratver, Taha Yazal, Kevin Dong, Andrea Nguyen, Garrett Yu, Amy Dao, Michael Bochkur Dratver, Sara Duhachek- Muggy, Kruttika Bhat, Claudia Alli, Frank Pajonk, Erina Vlashi Tags: Biology Contribution Source Type: research
More News: Alli | Biology | Breast Cancer | Cancer | Cancer & Oncology | Physics | Radiation Therapy | Radiology | Stem Cell Therapy | Stem Cells | Study